Biomarkers of residual disease at surgery identify which triple-negative breast cancer patients already treated with neoadjuvant therapy will do well and which will do poorly over the next 2 years.
A hashtag that gained a lot of traction during the COVID-19 pandemic is, thankfully, in decline, but can we avoid buying into such nonsense again?
Familial hypercholesterolemia is often diagnosed late, and patients with the condition are significantly undertreated.
Investigators assess the impact of increasing persistent PSA levels on prostate cancer–specific mortality and all-cause mortality risk.
Join this dynamic expert dialogue about the latest data on lymphocyte activating gene 3 (LAG-3) inhibitors in advanced cutaneous melanoma.
Longer term use of a skin patch helps treat peanut allergies in some children, a new study finds.
Early measurable residual disease clearance is linked to better outcomes in acute myeloid leukemia, study suggests.
The patient’s past medical history is notable only for hypothyroidism.
Studies suggest psychotropic polypharmacy may be on the rise. But experts say whether that’s good or bad — or even unavoidable — is more nuanced.
A retrospective study highlights the high misdiagnosis rates of dermatomyositis, particularly its amyopathic subtype, and the associated increase in hospitalizations and worse lung function.
Future research will show whether the change in the availability of hallucinogens affects the risks associated with these drugs.
